Bone drug Zometa flops in breast cancer study

Dec 09, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- Doctors are reporting a stunning setback for a promising new approach for fighting breast cancer.

A large study found that the bone-building drug Zometa (zow-MAY-tuh) did not prevent the return of cancer or improve survival in women with early or mid-stage disease.

Zometa did seem to help women at least five years past or over 60. The drug's maker, Novartis AG, is considering further tests in those women. Studies also are testing similar drugs, bisphosphonates like Fosamax and Boniva, to see if they help prevent .

Zometa is currently used to treat cancer that has already spread to the bone. The new study will not change that or affect the use of other similar drugs for .

Explore further: Green tea ingredient may target protein to kill oral cancer cells

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Novel cancer drug has potential, study reports

Nov 12, 2010

(PhysOrg.com) -- Monthly injections of the drug in breast cancer patients whose disease had spread to the bone helped reduce pain and prevent complications with less toxicity than current treatments.

FDA warns of fractures with osteoporosis drugs

Oct 13, 2010

(AP) -- Government health officials warned doctors and patients Wednesday about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs.

Breast cancer study halted

Jun 20, 2007

The U.S. National Cancer Institute halted a $100 million study of drugs designed to prevent breast cancer in women at risk for the disease.

Recommended for you

Elucidating the origin of MDR tuberculosis strains

2 hours ago

A study has focused on the evolutionary history of the mycobacterium that causes tuberculosis, and more specifically on the Beijing lineage associated with the spread of multidrug resistant forms of the disease ...

Mexico escalating the fight against breast cancer

3 hours ago

On Avenue San Fernando, a tree-lined street crowded with food stands, the new wing of Mexico's flagship cancer hospital gleams like a silver airplane. Barely a year old, the light-filled structure attached to the National ...

Core needle biopsy helpful with cervical lymphadenopathy

19 hours ago

(HealthDay)—Core needle biopsy (CNB) is a more sensitive tool than fine-needle aspiration cytology (FNAC) for cervical lymphadenopathy evaluation, according to a study published in the February issue of ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.